ETICA & SICUREZZA

Bruno Mourenza, APRE

15 Luglio 2021
Widening Participation and Strengthening the European Research Area

Pillar 1: Excellent Science
- European Research Council
- Marie Skłodowska-Curie
- Research Infrastructures
- Joint Research Centre

Pillar 2: Global Challenges & European Industrial Competitiveness
- Health & Culture
- Industry & Space
- Climate, Energy & Mobility
- Food, Bioeconomy, Natural Resources, Agriculture & Environment
- European Innovation Council
- European innovation ecosystems
- European Institute of Innovation & Technology

Widening participation & spreading excellence
Reforming & Enhancing the European R&I system

* The European Institute of Innovation & Technology (EIT) is not part of the Specific Programme

ETHICS ISSUES
Agenda

1) Introduction
2) Objective - Ethical principles
3) Legal Basis
4) Before GA signature - Proposal preparation and Evaluation Stage
5) After GA signature - Checks, Reviews and Audits
6) Tricks and tips
1) Introduction

• Ethics is a consideration for all EU funded projects in all research domains
• Ethics are integral to all research, from beginning to end
• Considering ethics:
  • Ensures it is within the legal framework
  • Enhances the quality of research (e.g. RRI)
• Strong connection between research ethics and human rights
• Ethics process for Horizon 2020 – Ethics Appraisal Procedure
Why an “Ethical review”? 

✓ Awareness of applicants on the ethical/social impact of research

✓ Application of relevant EU Directives/Regulations international conventions/declarations and codes of conduct (ie: Data Protection Directive, Clinical trials directive, Animal welfare directive)

✓ Approval of relevant local/national (ethics) committees

✓ Respect of H2020 ethical standards
2) Objective

“In addition to the scientific evaluation focusing on the scientific merit, the quality of the management and the potential impact, the Ethics Appraisal ensures that all research activities carried out under the Horizon 2020 Framework Programme are conducted in compliance with fundamental ethical principles.”(*)

Art. 19 - HE Framework Programme Regulation 2021/695
*Main Ethical Principles*

- Respect **human dignity and integrity**
- Ensuring honesty and **transparency** towards research subjects - **free and informed consent (as well as assent whenever relevant)**
- Protect **vulnerable persons**
- Ensure **privacy and confidentiality**
- Promote justice and inclusiveness
- **Minimise harm and maximising benefit**
- Share **benefits with disadvantaged populations**, especially if the research is being carried out in developing countries
- Maximise **animal welfare** - *in particular by ensuring Replacement, Reduction and Refinement (‘3Rs’) in animal research*
- **Respect and protect the environment** and future generations

Art. 19 - HE Framework Programme Regulation 2021/695
3) Legal Basis

**Rules of participation:**

«A proposal which contravenes ethical principles or any applicable legislation, or which does not fulfill the conditions set out in Decision No 2013/743/EU, in the work programme, in the work plan or in the call for proposals may be excluded from the evaluation, selection and award procedures at any time."»

**Rules of participation:**

«The Commission shall systematically carry out ethics reviews for proposals raising ethical issues. That review shall verify the respect of ethical principles and legislation and, in the case of research carried out outside the Union, that the same research would have been allowed in a Member State. »

Art. 19 - HE Framework Programme Regulation 2021/695
Fields of research not eligible

✓ Research activity aiming at human cloning for reproductive purposes;

✓ Research intended to modify the genetic heritage of human beings which could make such changes heritable;

✓ Research activities intended to create human embryos solely for the purpose of research or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer.

✓ Destruction of human embryos (for example, for obtaining stem cells)

Art. 18 - HE Framework Programme Regulation 2021/695
4) Proposal and Evaluation Stage

• Applicants should proactively demonstrate that all ethical issues have been considered

• Applications should be ‘Ethics Ready’
ONLINE SUBMISSION FORMS

PROPOSAL

PART A
Administrative

PART B
Technical
Single stage (or 2nd stage)

**PARTE A**

1) General Information
2) Participants
3) Budget
4) Ethics and Security
5) Other questions

*Template pdf online on the Participant Portal*

**PARTE B**

1) Excellence
   1.1) Objectives and ambition
   1.2) Methodology
   1.3) Concept and Approach

2) Impact
   2.1) Project’s pathways towards impact
   2.2) Measures to maximise impact - Dissemination, exploitation and communication
   2.3) Summary

3) Implementation
   3.1) Work plan and resources
   3.2) Capacity of participants and consortium as a whole

*Word Document downloadable from the Participant Portal*

45 pages max.
### 1 - General information

Section 1 provides basic data on the proposal. It can be filled in by contacts of the coordinator. Other participants may view this section only. Read-only parts are marked in blue.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Type of action</th>
<th>Type of Model/Grant Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Acronym**
Acronym is mandatory

**Proposal title**
Max 200 characters (with spaces). Must be understandable for non-specialists in your field.

Note that for technical reasons, the following characters are not accepted in the Proposal Title and will be removed: & * ^ $.

**Duration in months**
Estimated duration of the project in n/mnths.

**Fixed keyword**

**Free keywords**
Enter any words you think give extra detail of the scope of your proposal (max 200 characters with spaces).

**Abstract**
The abstract should provide the reader with a clear understanding of the objectives of the proposal, how they will be achieved, and their relevance to the Work Programme. This summary will be used in the selection of the proposal in the evaluation process and in communications to the programme management committee and other interested parties. It must therefore be short and precise and should not contain confidential information. Use plain text, avoiding LaTeX and other special characters. If the proposal is written in a language other than English, please include an English version of this abstract in the Part B (technical description) of the proposal.

Has this proposal (or a very similar one) been submitted in the past 2 years in response to a call for proposals under any EU programme, including the current call? A "similar" proposal or contrast is one that differs from the current one in minor ways, and in which some of the present consortium members are involved.

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

Please give the proposal reference or contract number: XXXXX-X
### Ethics Issues Table – 10 Questions:

1. **HUMAN EMBRYONIC STEM CELLS AND HUMAN EMBRYOS**
   - Does this activity involve Human Embryonic Stem Cells (HESCs)?
     - Yes
     - No
   - If YES: Will they be directly derived from embryos within this project?
     - Yes
     - No
   - Are they previously established cell lines?
     - Yes
     - No
   - Are the cell lines registered in the European registry for human embryonic stem cell lines?
     - Yes
     - No

2. **HUMANS**
   - Does this activity involve human participants?
     - Yes
     - No
   - If YES: Are they volunteers for nonmedical studies (e.g., social or human sciences research)?
     - Yes
     - No
   - Are they healthy volunteers for medical studies?
     - Yes
     - No
   - Are they patients for medical studies?
     - Yes
     - No
   - Are they potentially vulnerable individuals or groups?
     - Yes
     - No
   - Are they children/teenagers?
     - Yes
     - No
   - Are they other persons unable to give informed consent?
     - Yes
     - No

   - Does this activity involve interventions (physically including imaging technology, behavioural treatments, etc.) on the study participants?
     - Yes
     - No
   - If YES: Does it involve invasive techniques?
     - Yes
     - No
   - Does it involve collection of biological samples?
     - Yes
     - No

   - Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU) 536/2012 (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products)?
     - Yes
     - No

If ‘yes’ for any questions, ethics self-assessment to be completed in Part A *(next slide)*
Proposal Part A

Section 4 ‘Ethics Issues Table’ – Explanation:

**Explanation about how you will deal with your Ethics issues in the proposal**

<table>
<thead>
<tr>
<th>Ethical dimension of the objectives, methodology and likely impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explain in detail the identified issues in relation to:</td>
</tr>
<tr>
<td>- objectives of the activities (e.g. study of vulnerable populations, etc.)</td>
</tr>
<tr>
<td>- methodology (e.g. clinical trials, involvement of children, protection of personal data, etc.)</td>
</tr>
<tr>
<td>- the potential impact of the activities (e.g. environmental damage, stigmatisation of particular social groups, political or financial adverse consequences, misuse, etc.)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Compliance with ethical principles and relevant legislations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Describe how the issue(s) identified in the ethics issues table above will be addressed in order to adhere to the ethical principles and what will be done to ensure that the activities are compliant with the EU/national legal and ethical requirements of the country or countries where the tasks are to be carried out. It is reminded that for activities performed in a non-EU countries, they should also be allowed in at least one EU Member State.</td>
</tr>
</tbody>
</table>

Provide appropriate documents as evidence

If not, timeframe for approvals/ authorizations
Proposal Part A

- Section 4 ‘Ethics Issues Table’ – 10 Questions:

  1. Human embryo*/foetuses
  2. Humans*
  3. Human cells/tissues*
  4. Protection of personal data (collection, recording, storage, deleting)
  5. Animals (favour alternative methods – 3 R’s: Replacement, Reduction, Refinement)
  6. Non-EU countries* (prohibited in EU, exploitation, risks)
  7. Environment, Health, Safety (fauna/flora, humans, research staff)
  8. Dual-use (military application!?)
  9. Exclusive focus on civil applications
  10. Misuse (malevolent use of research results)
  11. Other ethics issues

* Informed consent/Information sheet

In Horizon Europe, substituted by section:
- **Human embryonic stem cells (hESCs) and human embryos (hEs)**
- **Artificial intelligence**

How to complete your Ethics self-assessment
Proposal Part A

• Section 4 ‘Ethics Issues Table’ – 10 Questions:

1. Human embryonic stem cells (hESCs) and human embryos (hEs)

hESCs - Are they previously established cells lines?
Are the cell lines registered in the European registry for human embryonic stem cell lines?

hEs - Does your activity involve the use of human embryos?

1) Copies of ethics approval.
2) Declaration that the human embryonic stem cell lines used in the project are registered in the European hESC registry (www.hpscreg.eu).

1) Copies of ethics approval.
2) Informed consent forms and information sheets.
• Proposal Part A

Section 4 ‘Ethics Issues Table’ – 10 Questions:

2. Humans beings

- Are they **volunteers for nonmedical studies** (e.g. social or human sciences research)?
- Are they **healthy volunteers for medical studies**?
- Are they **patients for medical studies**?
- Are they **vulnerable individuals or groups**?
- Are they **children/minors**?
- Are they **persons unable to give informed consent**?
### 3. Human cells or tissues

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does your activity involve human cells or tissues?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are they human embryonic or foetal cells or tissues?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are they available commercially?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are they obtained within this project?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are they obtained from another project, laboratory or institution?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are they obtained from a biobank?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**If Yes:**
- Origin of human foetal tissues/cells.
- Details on informed consent procedures.
- Confirmation that the informed consent has been obtained.
- If applicable, details on the induced human pluripotent cell lines.

**If No:**
- Details on cell types and provider (company or other).

### Instructions

1. Copies of ethics approvals.
2. Informed consent forms and information sheets.

### Additional Information

- If applicable, registration certificates of the cell lines and project from the hPSCreg.
- Copies of import licenses (if relevant).
- Informed consent forms and information sheets.

---

1. Authorization by primary owner of cells/tissues (including references to ethics approvals)
2. Copies of import licenses (if relevant).
3. Statement from the primary laboratory/institute on that informed consent has been obtained.

---

1. Copies of import licenses (if relevant).
2. Statement of biobank that informed consent has been obtained.
4. Personal data

- Does your activity involve **processing of personal data**?

- Does your activity involve **further processing of previously collected personal data** (including use of pre-existing data sets or sources, merging existing data sets)?

- Is it planned to **export personal data** (data transfer) from the EU to non-EU countries? **Specify the type of personal data and countries involved**

- Is it planned to **import personal data** (data transfer) from non-EU countries into the EU or from a non-EU country to another non-EU country? **Specify the type of personal data and countries involved**

- Does this activity involve the processing of **personal data related to criminal convictions or offences**?

---

1. Information
   - Confirmation that the data controller has a lawful basis for the data processing.
   - Technical and organisational safeguarding measures.
   - Permission by data subjects (e.g., social media).

2. Data protection
   - Confirmation that data transfers will be made in accordance with General Data Protection Regulation (GDPR).
   - Opinion of the data controller on the need for conducting data protection impact assessment under Article 35 GDPR (if relevant).

3. Data assessment
   - Informed Consent Forms + Information Sheets + other consent documents (if applicable).
5. Animals

- Does your research involve animals?

  If YES:

  Are they vertebrates?  
  ☐ ☐ Same information as above.

  Are they non-human primates (NHP) (e.g. monkeys, chimpanzees, gorillas, etc.)?  
  ☐ ☐ Same information as above plus:
  1) Justification on why NHPs are the only research subjects suitable for achieving your scientific objectives.
  2) Details on the purpose of the animal testing.
  3) Details on the origin of the animals.

  Are they genetically modified?  
  ☐ ☐ 1) Number of animals to be used, nature of the experiments, procedures, anticipated impact and how this will be minimized.
  2) Details on species and rationale for their use.
  3) Details on procedures to ensure animal welfare.
  4) Details on implementation of the 3Rs Principle.

  Are they cloned farm animals?  
  ☐ ☐ Same information as above.

  Are they an endangered species?  
  ☐ ☐ 1) Justification on why there is no alternative to using this species.
  2) Details on the purpose of the research.

  Ministero della Salute:  
  Autorizzazione di progetti di ricerca con l'impiego di animali a fini scientifici

1) Copies of all appropriate authorizations for the supply of animals and the project experiments.
2) Copies of training certificates/personal licenses of the staff involved in animal experiments.

Same documents as above plus:
1) Personal history file of NHP (See art. 31 of Directive 2010/63).

1) Copies of all appropriate authorizations for the supply of animals and the project experiments.
2) Copies of training certificates/personal licenses of the staff involved in animal experiments.

1) Copies of all appropriate authorizations for the supply of animals and the project experiments.
2) Copies of training certificates/personal licenses of the staff involved in animal experiments.
3) Copies of authorizations for cloning (if required).

1) Copies of authorizations for supply of endangered animal species (including CITES) and the project experiments.
2) Copies of training certificates/personal licenses of the staff involved in animal experiments.
6. Non-EU countries

- In case **non-EU countries are involved**, do the activities undertaken in these countries raise potential ethics issues?
- Is it planned to use **local resources**?
- Is it planned to **import any material** (other than data) from non-EU countries into the EU or from a non-EU country to another non-EU country? or **export any material** (other than data) from the EU to non-EU countries?
- Does your activity involve **low and/or lower-middle income countries**, are any benefit-sharing actions planned?
- Could the **situation in the country** put the individuals taking part in the activity at risk?
7. Environment, health & safety

- Environment
- Health and safety

<table>
<thead>
<tr>
<th>Section 7: ENVIRONMENT, HEALTH AND SAFETY</th>
<th>YES/NO</th>
<th>Information to be provided in the proposal</th>
<th>Documents to be provided on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does this activity involve the use of substances or processes (or technologies) that may cause harm to humans, including those performing the activity (during the implementation of the activity or further to the use of the results, or the deployment of the technology as a possible impact)?</td>
<td>YES/NO</td>
<td>Information to be provided in the proposal</td>
<td>Documents to be provided on request</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1) Details of the health and safety procedures.</td>
<td>1) Safety classification of laboratory. 2) Host Institution safety procedures.</td>
</tr>
</tbody>
</table>

*For activities involving human participants, see section 2.*
8. Dual use*

| Does this research involve dual-use items in the sense of Regulation 428/2009, or other items for which an authorisation is required? | ☐ | ☐ | What goods and information used and produced in your research will need export licences? | Copies of export licences. |
| | | | How exactly will you ensure compliance? | |
| | | | How exactly will you avoid negative implications? | |

*These dual-use items are normally used for civilian purposes but may have military applications, or may contribute to the proliferation of weapons of mass destruction.


Guidance note — Research involving dual-use items
9. Exclusive focus on civil applications

Could your research raise concerns regarding the exclusive focus on civil applications?

- [ ] Explain the exclusive civilian focus of your research.
- [ ] Justify inclusion of military partners or military technologies (i.e. explain how they relate to civilian applications, e.g. in the context of law enforcement activities).

* This does not rule out the participation of military partners or the development of generic technologies, products or knowledge that may meet the needs of both civil and military end-users (known as 'dual-use' goods or technologies), provided that the research itself has a clear focus on civil applications.
Dual use – moved to PART A of the proposal - DECLARATIONS

7) We declare that the proposal has an exclusive focus on civil applications (activities intended to be used in military application or aiming to serve military purposes cannot be funded). If the project involves dual-use items in the sense of Regulation 428/2009, or other items for which authorisation is required, we confirm that we will comply with the applicable regulatory framework (e.g. obtain export/import licences before these items are used).
8. Artificial intelligence

<table>
<thead>
<tr>
<th>Section 8: ARTIFICIAL INTELLIGENCE</th>
<th>YES/NO</th>
<th>Information to be provided</th>
<th>Documents to be provided/kept on file</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does this activity involve the development, deployment and/or use of Artificial Intelligence?</td>
<td>☐ ☐</td>
<td>1) Explanation as to how the participants and/or end-users will be informed about: • their interaction with an AI system/technology (if relevant). • the abilities, limitations, risks and benefits of the proposed AI system/technique. • the manner in which decisions are taken and the logic behind them (if relevant).</td>
<td>1) Detailed risk assessment accompanied by a risk mitigation plan (if relevant). These must cover the development, deployment and post-deployment phases. 2) Copies of ethics approvals (if relevant).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Details on the measures taken to avoid bias in input data and algorithm design. 3) Explanation as to how the respect to fundamental human rights and freedoms (e.g. human autonomy, privacy and data protection) will be ensured. 4) Detailed explanation on the potential ethics risks and the risk mitigation measures.</td>
<td></td>
</tr>
</tbody>
</table>
8. Artificial intelligence

If YES:

Could the AI-based system/technique potentially stigmatize or discriminate against people (e.g. based on sex, race, ethnic or social origin, age, genetic features, disability, sexual orientation, language, religion or belief, membership to a political group, or membership to a national minority)?

Does the AI system/technique interact, replace or influence human decision-making processes (e.g. issues affecting human life, health, well-being or human rights, or economic, social or political decisions)?

Does the AI system/technique have the potential to lead to negative social (e.g. on democracy, media, labour market, freedoms, educational choices, mass surveillance) and/or environmental impacts either through intended applications or plausible alternative uses?

Does the AI to be developed/used in the project raise any other ethical issues not covered by the questions above (e.g., subliminal, covert or deceptive AI, AI that is used to stimulate addictive behaviours, life-like humanoid robots, etc.)?

---

1) Detailed explanation of the measures set in place to avoid potential bias, discrimination and stigmatization.

1) Detailed explanation on how humans will maintain meaningful control over the most important aspects of the decision-making process.

1) Detailed explanation on how the presence/role of the AI will be made clear and explicit to the affected individuals.

1) Justification of the need for developing/using this particular technology.

1) Detailed explanation of the measures set in place to mitigate the potential negative impacts during the research, development, deployment and post-deployment phase.

1) Detailed explanation on how the potential ethics issues will be addressed and the measures set in place to mitigate ethics risks.

1) Detailed risk assessment accompanied by a risk mitigation plan. These must cover the development, deployment and post-deployment phases.

---

Definizione di Intelligenza Artificiale
### 9. Other ethics issues

<table>
<thead>
<tr>
<th>Section 9: OTHER ETHICS ISSUES</th>
<th>YES/ NO</th>
<th>Information to be provided in the proposal</th>
<th>Documents to be provided on request</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are there any other ethics issues that should be taken into consideration?</td>
<td>☐ ☐</td>
<td>1) Any relevant information.</td>
<td>1) Any relevant document.</td>
</tr>
</tbody>
</table>

*Please specify*
10. Crosscutting issue: potential misuse of results

Research involving or generating materials, methods, technologies or knowledge that could be misused for unethical purposes. Although such research is usually carried out with benign intentions, it has the potential to harm humans, animals or the environment.

Activities most vulnerable to misuse could include:
- the development of surveillance technologies that could curtail human rights and civil liberties
- the involvement of minority or vulnerable groups or the development of social, behavioural or genetic profiling technologies that could be misused to stigmatise, discriminate against, harass or intimidate people
- the development of materials/methods/technologies and knowledge that could harm humans, animals or the environment if they were released, modified or enhanced.
- in general, the development of materials/methods/technologies and knowledge that could serve purposes other than those intended, and if so, in unethical ways.

Guidance note — Potential misuse of research results
Evaluation stage

• In addition to their scientific merit, all applications are evaluated on their *ethical* and social impact

• All proposals **above threshold** with a view to funding undergo an **Ethics Review:**
  • 1) Ethics Screening
  • 2) Ethics Assessment *(if necessary/recommended)*

• **Ongoing projects**: Checks/Reviews/Audits
Ethics Appraisal Procedure

The process to assess and address the ethical dimension of activities is called the **Ethics Appraisal Procedure**.
Ethics Clearance

Ethics review steps

- Pre-Screening
- Screening
- Assessment

Grant preparation

Does the proposal raise ethical issues?

- No ➔ ✓
- Yes ➔

Does the proposal address all ethical issues satisfactorily?

- Yes ➔ ✓
- No ➔ "Ethics requirements" are defined in order to close the gap.

Are all "ethics requirements" implemented in the grant agreement?

- Yes ➔ ✓

✓ = OK to sign grant agreement
## Ethics Appraisal Steps

<table>
<thead>
<tr>
<th>Activity</th>
<th>Who?</th>
<th>When?</th>
<th>How?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethics Self-assessment</td>
<td>Applicant</td>
<td>Application phase</td>
<td>Consideration of ethical issues of the proposal</td>
</tr>
<tr>
<td>Ethics Pre-screening/Screening</td>
<td>Ethics experts and/or qualified staff</td>
<td>Evaluation phase</td>
<td>Review of application material</td>
</tr>
<tr>
<td>Ethics Assessment (for proposals involving hESC or raising serious ethical issues: severe intervention on humans)</td>
<td>Ethics experts</td>
<td>Evaluation/Grant preparation phase</td>
<td>Review of application material</td>
</tr>
<tr>
<td>Ethics Check/Audit</td>
<td>Ethics experts</td>
<td>Implementation phase</td>
<td>Review of project deliverables/interview with applicants</td>
</tr>
</tbody>
</table>
## Security issues table

### 1. EU classified information (EUCI)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does this activity involve information and/or materials requiring protection against unauthorised disclosure (EUCI)?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>If YES: Is the activity going to use classified information as background information?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Is the activity going to generate EU classified foreground information as results?</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

### Does this activity involve HE associated and/or third countries?

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>If YES: Do participants from non-EU countries need to have access to EUCI?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Do the non-EU countries concerned have a security of information agreement with the EU</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

### 2. MISUSE

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does this activity have the potential for misuse of results?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>If YES: Does the activity provide knowledge, materials and technologies that could be channelled into crime and/or terrorism?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Could the activity result in the development of chemical, biological, radiological or nuclear (CBRN) weapons and the means for their delivery?</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

### 3. OTHER SECURITY ISSUES

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does this activity involve information and/or materials subject to national security restrictions?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>If yes, please specify: (Maximum number of characters allowed: 1000)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are there any other security issues that should be taken into consideration?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>If yes, please specify: (Maximum number of characters allowed: 1000)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Art. 20 - HE Framework Programme Regulation 2021/695*
CHIEDI SUPPORTO AI TEAM TEMATICI IN APRE

www.horizon-europe.it
PER NON PERDERTI GLI AGGIORNAMENTI

REGISTRATI A APRE MAILING

www.apre.it